Exacerbation severity and frequency are crucial for the prognosis of COPD, but also appear to have a major impact on the course of comorbidities. There is a growing body of evidence showing that COPD patients are at increased risk of cardiovascular events, with the frequency and severity of exacerbations being important predictors. Optimal treatment of COPD also appears to reduce the risk of concomitant diseases. Depending on the situation, it may make sense to extend dual bronchodilation with inhaled steroids or roflumilast as an add-on.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Symptom-free despite asthma?
Asthma treatment requirements have increased
- Phytotherapy for rhinosinusitis
Evidence, active substances and clinical classification for medical practice
- Pulmonary hypertension
PH and lung diseases
- Contact eczema
Causes and prevention at work
- Respiratory infections: viral bronchitis or bacterial pneumonia?
Old crucial question in the light of current findings
- What biomarkers reveal about "biological youth" - and what not (yet)
Epigenetic ageing
- Amyotrophic lateral sclerosis and nutrition
Calorie optimization in ALS through digital intervention
- "Forgotten axis" between plant substances, gut and systemic health